Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI
Journal article

Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI

  • Copelan, Edward A. Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC;
  • Hamilton, Betty K. Cleveland Clinic Foundation, Cleveland, OH;
  • Avalos, Belinda Levine Cancer Institute, Carolinas Healthcare System, Charlotte, NC;
  • Ahn, Kwang Woo Center for International Blood and Marrow Transplant Research, Milwaukee, WI;
  • Bolwell, Brian J. Cleveland Clinic Foundation, Cleveland, OH;
  • Zhu, Xiaochun Center for International Blood and Marrow Transplant Research, Milwaukee, WI;
  • Aljurf, Mahmoud King Faisal Specialist Hospital Center and Research, Riyadh, Saudi Arabia;
  • van Besien, Koen Weill Cornell Medical College, New York, NY;
  • Bredeson, Christopher Division of Hematology, Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada;
  • Cahn, Jean-Yves Department of Hematology, University Hospital, Grenoble, France;
  • Costa, Luciano J. Medical University of South Carolina, Charleston, SC;
  • de Lima, Marcos University Hospitals Case Medical Center, Cleveland, OH;
  • Gale, Robert Peter Imperial College, Section of Hematology, Division of Experimental Medicine, Department of Medicine, London, United Kingdom;
  • Hale, Gregory A. All Children’s Hospital, St. Petersburg, FL;
  • Halter, Joerg University Hospital Basel, Basel, Switzerland;
  • Hamadani, Mehdi West Virginia University Hospitals, Morgantown, WV;
  • Inamoto, Yoshihiro Fred Hutchinson Cancer Research Center, Seattle, WA;
  • Kamble, Rammurti T. Baylor College of Medicine Center for Cell and Gene Therapy, Houston, TX;
  • Litzow, Mark R. Mayo Clinic Rochester, Rochester, MN;
  • Loren, Alison W. Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA;
  • Marks, David I. Bristol Children’s Hospital, Bristol, United Kingdom;
  • Olavarria, Eduardo Catherine Lewis Center, Pamplona, Spain;
  • Roy, Vivek Mayo Clinic, Jacksonville, FL;
  • Sabloff, Mitchell Division of Hematology, Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada;
  • Savani, Bipin N. Vanderbilt University Medical Center, Brentwood, TN;
  • Seftel, Matthew Cancer Care Manitoba/University of Manitoba, Winnipeg, Manitoba, Canada;
  • Schouten, Harry C. Academische Ziekenhuis Maastricht, Maastricht, The Netherlands;
  • Ustun, Celalettin University of Minnesota Medical Center, Fairview, Minneapolis, MN;
  • Waller, Edmund K. Emory University Hospital, Atlanta, GA;
  • Weisdorf, Daniel J. University of Minnesota Medical Center, Fairview, Minneapolis, MN;
  • Wirk, Baldeep Shands HealthCare and University of Florida, Gainesville, FL;
  • Horowitz, Mary M. Center for International Blood and Marrow Transplant Research, Milwaukee, WI;
  • Arora, Mukta University of Minnesota Medical Center, Fairview, Minneapolis, MN;
  • Szer, Jeff Royal Melbourne Hospital City Campus, Victoria, Australia;
  • Cortes, Jorge MD Anderson Cancer Center, Houston, TX; and
  • Kalaycio, Matt E. Cleveland Clinic Foundation, Cleveland, OH;
  • Maziarz, Richard T. Oregon Health and Science University, Portland, OR
  • Saber, Wael Center for International Blood and Marrow Transplant Research, Milwaukee, WI;
Show more…
Published in:
  • Blood. - American Society of Hematology. - 2013, vol. 122, no. 24, p. 3863-3870
English Key Points
In combination with cyclophosphamide, intravenous busulfan is associated with better leukemia-free and overall survival in AML than TBI.
Language
  • English
Open access status
green
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/81486
Statistics

Document views: 46 File downloads: